Is BioLife Solutions Stock a Good Investment?
BioLife Solutions Investment Advice | BLFS |
- Examine BioLife Solutions' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioLife Solutions' leadership team and their track record. Good management can help BioLife Solutions navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact BioLife Solutions' business and its evolving consumer preferences.
- Compare BioLife Solutions' performance and market position to its competitors. Analyze how BioLife Solutions is positioned in terms of product offerings, innovation, and market share.
- Check if BioLife Solutions pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioLife Solutions' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioLife Solutions stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioLife Solutions is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine BioLife Solutions Stock
Researching BioLife Solutions' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The book value of BioLife Solutions was currently reported as 7.04. The company has Price/Earnings (P/E) ratio of 173.59. BioLife Solutions recorded a loss per share of 1.11. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 29th of January 2014.
To determine if BioLife Solutions is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioLife Solutions' research are outlined below:
BioLife Solutions had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 143.27 M. Net Loss for the year was (66.43 M) with profit before overhead, payroll, taxes, and interest of 54.07 M. | |
BioLife Solutions currently holds about 46.55 M in cash with (12.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
BioLife Solutions has a frail financial position based on the latest SEC disclosures | |
Over 100.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from thelincolnianonline.com: BioLife Solutions Stock Price Up 6.7 percent Heres What Happened |
BioLife Solutions uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioLife Solutions. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioLife Solutions' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BioLife Solutions' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioLife Solutions' investors have experienced.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-05-13 | 2021-03-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2020-05-14 | 2020-03-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2019-05-09 | 2019-03-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2019-03-14 | 2018-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2018-11-08 | 2018-09-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2018-08-09 | 2018-06-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2018-03-08 | 2017-12-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2017-05-11 | 2017-03-31 | -0.05 | -0.04 | 0.01 | 20 |
Know BioLife Solutions' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioLife Solutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLife Solutions backward and forwards among themselves. BioLife Solutions' institutional investor refers to the entity that pools money to purchase BioLife Solutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Geneva Capital Management | 2024-09-30 | 865.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 846.6 K | Geode Capital Management, Llc | 2024-09-30 | 842.8 K | Royce & Associates, Lp | 2024-09-30 | 825.1 K | Palisade Capital Management Llc | 2024-09-30 | 821.1 K | Granahan Investment Management Inc.. | 2024-09-30 | 658.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 584.3 K | Gagnon Securities Llc | 2024-09-30 | 569.4 K | Bank Of America Corp | 2024-06-30 | 544.1 K | Casdin Capital, Llc | 2024-09-30 | 8.7 M | Blackrock Inc | 2024-06-30 | 5.5 M |
BioLife Solutions' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.21 B.Market Cap |
|
BioLife Solutions' profitablity analysis
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.40) | (0.42) | |
Return On Capital Employed | (0.19) | (0.20) | |
Return On Assets | (0.16) | (0.17) | |
Return On Equity | (0.20) | (0.21) |
Determining BioLife Solutions' profitability involves analyzing its financial statements and using various financial metrics to determine if BioLife Solutions is a good buy. For example, gross profit margin measures BioLife Solutions' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioLife Solutions' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioLife Solutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLife Solutions. Check BioLife Solutions' Beneish M Score to see the likelihood of BioLife Solutions' management manipulating its earnings.
Evaluate BioLife Solutions' management efficiency
BioLife Solutions has return on total asset (ROA) of (0.0597) % which means that it has lost $0.0597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1504) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.2 in 2024. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 306.7 M in 2024, whereas Intangible Assets are likely to drop slightly above 19.5 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 7.72 | 8.11 | |
Tangible Book Value Per Share | 2.10 | 1.11 | |
Enterprise Value Over EBITDA | (15.87) | (16.66) | |
Price Book Value Ratio | 2.10 | 2.00 | |
Enterprise Value Multiple | (15.87) | (16.66) | |
Price Fair Value | 2.10 | 2.00 | |
Enterprise Value | 717.7 M | 753.6 M |
The strategic decisions made by BioLife Solutions management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Beta 1.883 |
Basic technical analysis of BioLife Stock
As of the 25th of November, BioLife Solutions shows the Mean Deviation of 2.76, downside deviation of 3.94, and Risk Adjusted Performance of 0.0413. BioLife Solutions technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BioLife Solutions coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if BioLife Solutions is priced correctly, providing market reflects its regular price of 26.77 per share. Given that BioLife Solutions has jensen alpha of (0.06), we suggest you to validate BioLife Solutions's prevailing market performance to make sure the company can sustain itself at a future point.BioLife Solutions' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioLife Solutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioLife Solutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioLife Solutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioLife Solutions' Outstanding Corporate Bonds
BioLife Solutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLife Solutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Solutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
BIOGEN INC 405 Corp BondUS09062XAF06 | View | |
BIOGEN INC Corp BondUS09062XAG88 | View | |
BIOGEN INC Corp BondUS09062XAH61 | View | |
BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
MGM Resorts International Corp BondUS552953CD18 | View |
Understand BioLife Solutions' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioLife Solutions' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | 0.0413 | |||
Market Risk Adjusted Performance | 0.0982 | |||
Mean Deviation | 2.76 | |||
Semi Deviation | 3.78 | |||
Downside Deviation | 3.94 | |||
Coefficient Of Variation | 2304.21 | |||
Standard Deviation | 3.78 | |||
Variance | 14.28 | |||
Information Ratio | 0.0088 | |||
Jensen Alpha | (0.06) | |||
Total Risk Alpha | (0.44) | |||
Sortino Ratio | 0.0084 | |||
Treynor Ratio | 0.0882 | |||
Maximum Drawdown | 18.63 | |||
Value At Risk | (5.60) | |||
Potential Upside | 6.19 | |||
Downside Variance | 15.51 | |||
Semi Variance | 14.31 | |||
Expected Short fall | (2.77) | |||
Skewness | 0.0878 | |||
Kurtosis | 1.64 |
Risk Adjusted Performance | 0.0413 | |||
Market Risk Adjusted Performance | 0.0982 | |||
Mean Deviation | 2.76 | |||
Semi Deviation | 3.78 | |||
Downside Deviation | 3.94 | |||
Coefficient Of Variation | 2304.21 | |||
Standard Deviation | 3.78 | |||
Variance | 14.28 | |||
Information Ratio | 0.0088 | |||
Jensen Alpha | (0.06) | |||
Total Risk Alpha | (0.44) | |||
Sortino Ratio | 0.0084 | |||
Treynor Ratio | 0.0882 | |||
Maximum Drawdown | 18.63 | |||
Value At Risk | (5.60) | |||
Potential Upside | 6.19 | |||
Downside Variance | 15.51 | |||
Semi Variance | 14.31 | |||
Expected Short fall | (2.77) | |||
Skewness | 0.0878 | |||
Kurtosis | 1.64 |
Consider BioLife Solutions' intraday indicators
BioLife Solutions intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLife Solutions stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioLife Solutions Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 1st of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
BioLife Stock media impact
Far too much social signal, news, headlines, and media speculation about BioLife Solutions that are available to investors today. That information is available publicly through BioLife media outlets and privately through word of mouth or via BioLife internal channels. However, regardless of the origin, that massive amount of BioLife data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioLife Solutions news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioLife Solutions relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioLife Solutions' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioLife Solutions alpha.
BioLife Solutions Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioLife Solutions can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioLife Solutions Corporate Management
Sarah JD | Chief Officer | Profile | |
Troy Wichterman | Chief Officer | Profile | |
Geraint Phillips | Senior Operations | Profile | |
Troy CPA | Chief Officer | Profile |
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.